Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 5/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.50 |
| ▸ | PPP5C | P53041 | 2/20 | 0.50 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731305 | 0.85 | TFPI2 (0.70) | TFPI2HSD11B1PPP5CPPP2CANPY4R | |
| SCHEMBL9880154 | 0.85 | TFPI2 (0.70) | TFPI2HSD11B1PPP5CPPP2CANPY4R | |
| SCHEMBL9881182 | 0.83 | TFPI2 (0.71) | TFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL20459535 | 0.79 | TFPI2 (0.63) | TFPI2HSD11B1PPP5CPPP2CANPY4R | |
| SCHEMBL13556913 | 0.79 | ALDH1A1 (0.53) | TFPI2KMT2ASMN1; SMN2 | |
| SCHEMBL13001884 | 0.78 | TFPI2 (0.49) | TFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL20381220 | 0.72 | HSD11B1 (0.54) | HSD11B1PPP5CPPP2CAKMT2A | |
| SCHEMBL7903517 | 0.71 | HSD11B1 (0.82) | HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL9880153 | 0.69 | HSD11B1 (0.45) | TFPI2HSD11B1PPP5CPPP2CANPY4R | |
| SCHEMBL12632673 | 0.68 | HSD11B1 (0.89) | HSD11B1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2124550-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8426444-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885HSD11B1 56/4885PPP5C 3037/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TFPI2 4843/4885HSD11B1 79/4885PPP5C 2860/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885HSD11B1 56/4885PPP5C 3037/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885HSD11B1 56/4885PPP5C 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.